Headlands Technologies LLC Acquires 79,609 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Headlands Technologies LLC increased its holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 731.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,495 shares of the biotechnology company’s stock after acquiring an additional 79,609 shares during the quarter. Headlands Technologies LLC owned about 0.06% of Heron Therapeutics worth $317,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. Orchard Capital Management LLC increased its stake in shares of Heron Therapeutics by 4.7% in the 4th quarter. Orchard Capital Management LLC now owns 2,243,426 shares of the biotechnology company’s stock worth $3,814,000 after acquiring an additional 100,603 shares in the last quarter. Panagora Asset Management Inc. increased its stake in shares of Heron Therapeutics by 49.8% in the 2nd quarter. Panagora Asset Management Inc. now owns 562,228 shares of the biotechnology company’s stock worth $1,968,000 after acquiring an additional 186,802 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Heron Therapeutics by 33.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 449,212 shares of the biotechnology company’s stock worth $1,572,000 after acquiring an additional 113,655 shares in the last quarter. Commonwealth Equity Services LLC increased its stake in shares of Heron Therapeutics by 3.1% in the 1st quarter. Commonwealth Equity Services LLC now owns 338,526 shares of the biotechnology company’s stock worth $938,000 after acquiring an additional 10,122 shares in the last quarter. Finally, Richmond Brothers Inc. increased its stake in shares of Heron Therapeutics by 188.0% in the 4th quarter. Richmond Brothers Inc. now owns 296,706 shares of the biotechnology company’s stock worth $504,000 after acquiring an additional 193,697 shares in the last quarter. 80.01% of the stock is currently owned by institutional investors.

Heron Therapeutics Stock Performance

NASDAQ:HRTX opened at $1.87 on Friday. The firm has a market cap of $283.62 million, a P/E ratio of -3.07 and a beta of 1.80. Heron Therapeutics, Inc. has a fifty-two week low of $0.50 and a fifty-two week high of $3.93. The firm has a 50-day simple moving average of $2.43 and a two-hundred day simple moving average of $2.80.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The firm had revenue of $36.02 million for the quarter, compared to analysts’ expectations of $35.35 million. During the same quarter in the previous year, the firm posted ($0.35) earnings per share. On average, equities research analysts predict that Heron Therapeutics, Inc. will post -0.1 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Rodman & Renshaw assumed coverage on shares of Heron Therapeutics in a research note on Thursday, June 13th. They set a “buy” rating and a $7.00 price objective for the company. Needham & Company LLC restated a “buy” rating and set a $5.00 price objective on shares of Heron Therapeutics in a research note on Wednesday, August 7th.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.